Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

被引:317
作者
Jocham, D
Richter, A
Hoffmann, L
Iwig, K
Fahlenkamp, D
Zakrzewski, G
Schmitt, E
Dannenberg, T
Lehmacher, W
von Wietersheim, J
Doehn, C
机构
[1] Univ Lubeck, Sch Med, Dept Urol, D-23538 Lubeck, Germany
[2] Klinikum St Georg, Dept Urol, Leipzig, Germany
[3] Wald Klinikum Gera, Dept Urol, Gera, Germany
[4] Klinikum Meiningen, Dept Urol, Meiningen, Germany
[5] Ruppiner Kliniken, Dept Urol, Neuruppin, Germany
[6] Eichsfeld Klinikum Haus Reifenstein, Dept Urol, Reifenstein, Germany
[7] Kreiskliniken Aschersleben Stassfurt, Dept Urol, Aschersleben, Germany
[8] Klinikum Offenbach, Dept Urol, Offenbach, Germany
[9] Univ Cologne, Sch Med, Inst Med Stat Informat & Epidemiol, Cologne, Germany
[10] Univ Ulm, Sch Med, Dept Psychosomat Med & Psychotherapy, Ulm, Germany
关键词
D O I
10.1016/S0140-6736(04)15590-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Organ-confined renal-cell carcinoma is associated with tumour progression in up to 50% of patients after radical nephrectomy. At present, no effective adjuvant treatment is established. We aimed to investigate the effect of an autologous renal tumour cell vaccine on risk of tumour progression in patients with stage pT2-3b pNO-3 MO renal-cell carcinoma. Methods Between January, 1997, and September, 1998, 558 patients with a renal tumour scheduled for radical nephrectomy were enrolled at 55 institutions in Germany. Before surgery, all patients were centrally randomised to receive autologous renal tumour cell vaccine (six intradermal applications at 4-week intervals postoperatively; vaccine group) or no adjuvant treatment (control group). The primary endpoint of the trial was to reduce the risk of tumour progression, defined as progression or death. All patients were assessed after standardised diagnostic investigations at 6-month intervals for a minimum of 4.5 years. Findings By preoperative and postoperative inclusion criteria, 379 patients were assessable for the intention-to-treat analysis. At 5-year and 70-month follow-up, the hazard ratios for tumour progression were 1.58 (95% CI 1.05-2.37) and 1.59 (1.07-2.36), respectively, in favour of the vaccine group (p=0.0204, log-rank test). 5-year and 70-month progression-free survival rates were 77.4% and 72%, respectively, in the vaccine group and 67.8% and 59.3%, respectively, in the control group. The vaccine was well tolerated, with only 12 adverse events associated with the treatment. Interpretation Adjuvant treatment with autologous renal tumour cell vaccine in patients with renal-cell carcinoma after radical nephrectomy seems to be beneficial and can be considered in patients undergoing radical nephrectomy due to organ-confined renal-cell carcinoma of more than 2.5 cm in diameter.
引用
收藏
页码:594 / 599
页数:6
相关论文
共 32 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   THE EFFECT OF ALPHA-INTERFERON AND GAMMA-INTERFERON ON CELL-GROWTH AND HISTOCOMPATIBILITY ANTIGEN EXPRESSION BY HUMAN RENAL-CARCINOMA CELLS IN-VITRO [J].
ANGUS, R ;
COLLINS, CMP ;
SYMES, MO .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (13) :1879-1885
[3]   Vaccines in oncology: background and clinical potential [J].
Armstrong, AC ;
Hawkins, RE .
BRITISH JOURNAL OF RADIOLOGY, 2001, 74 (887) :991-1002
[4]  
BIANCO MD, 1988, EUR UROL, V15, P73
[5]   Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial [J].
Clark, JI ;
Atkins, MB ;
Urba, WJ ;
Creech, S ;
Figlin, RA ;
Dutcher, JP ;
Flaherty, L ;
Sosman, JA ;
Logan, TF ;
White, R ;
Weiss, GR ;
Redman, BG ;
Tretter, CPG ;
McDermott, D ;
Smith, JW ;
Gordon, MS ;
Margolin, KA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) :3133-3140
[6]   ANALYSIS OF IMAGING MODALITIES, STAGING SYSTEMS, AND PROGNOSTIC INDICATORS FOR RENAL-CELL CARCINOMA [J].
DINNEY, CPN ;
AWAD, SA ;
GAJEWSKI, JB ;
BELITSKY, P ;
LANNON, SG ;
MACK, FG ;
MILLARD, OH .
UROLOGY, 1992, 39 (02) :122-129
[7]  
Doehn C, 2003, FOLIA BIOL-PRAGUE, V49, P69
[8]   Non-nutritive bioactive food constituents of plants: Tocopherols (vitamin E) [J].
Elmadfa, I ;
Wagner, KH .
INTERNATIONAL JOURNAL FOR VITAMIN AND NUTRITION RESEARCH, 2003, 73 (02) :89-94
[9]   Renal cell carcinoma: Management of advanced disease [J].
Figlin, RA .
JOURNAL OF UROLOGY, 1999, 161 (02) :381-386
[10]  
Galligioni E, 1996, CANCER, V77, P2560, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2560::AID-CNCR20>3.0.CO